From The Stage

BioAgilytix Holds Ribbon Cutting to Celebrate Boston Lab Expansion, Additional Jobs and Tech Capabilities

Posted by BioAgilytix / /

BOSTON, Massachusetts – BioAgilytix, a leading bioanalytical laboratory specializing in large molecule bioanalysis, recently held a ribbon-cutting to celebrate the large-scale expansion of its leading-edge Boston laboratory. Located in the Cambridge, Massachusetts biopharma hub, the expanded CLIA-certified, CAP-accredited laboratory added 21-color flow cytometry and ddPCR, plus additional capacity for more qPCR, ADA/PK and biomarker testing to its already robust preclinical and clinical trials and diagnostic testing capabilities. “With our expanded Boston lab, larger scientific team and new instrumentation, we continue to lead the field in helping our biopharma customers capitalize…

[EPISODE 10] Jeff Sutherland Discusses Dogs: Canine Nutrition and Oncology Advances

Posted by BioAgilytix / /

In this episode, Chad sits down with Jeff Sutherland, founder and CEO of Canine Biologics. With over 500,000 dogs in the US and Canada diagnosed with cancer each year, Jeff’s company addresses nutritional needs for dogs to fight terminal diseases based on tumor type. They discuss how Jeff started off as pre-med in college before shifting his focus to marketing, then to dental technology, and finally to IT with a master’s in Artificial Intelligence before realizing his true passion…the health of dogs. Jeff shares how he was able to fulfill…

[EPISODE 9] Dr. Jolly Mazumdar and Tim Chendrimada Talks Dreaming Big, Coffee Beans and Self Amplifying RNA!

Posted by BioAgilytix / /

In today’s episode, Chad sits down with guest scientists, Dr. Jolly Mazumdar and Tim Chendrimada, CEO, and CSO of Chimeron Bio. Two different beginnings; one in the sciences studying bugs and infectious diseases and the other in agriculture, specifically coffee beans! They talk to Chad about how their very different paths led them to become a dynamic duo in the next generation of RNA therapeutics. From Tim asking a scientist of Wistar Institute to take a chance on him with no prior experience in medical science to Jolly traveling to…

[EPISODE 8] Dr. John Smeraglia Talks Globe Trotting, Italian Food, and Magnetic Sector Mass Spectrometers!

Posted by BioAgilytix / /

In today’s episode, Chad sits down with guest scientist, Dr. John Smeraglia, Vice President & Head of Translational Biomarkers and Bioanalysis at UCB. John is an experienced pharma leader in the development and service side of the industry. John talks to Chad about his experiences working in the UK, such as picking up basketball and taking apart a massive magnetic sector mass spectrometer in his early days of working in bioanalysis. They also discuss John’s transfer to San Diego, California, the language barriers encountered while working in Belgium and building…

[EPISODE 7] Angela Stoyanovitch Talks Detroit Pride, Legal Drugs, and the Google of CROs!

Posted by BioAgilytix / /

In today’s episode, Chad sits down with Angela Stoyanovitch, a director of business development at BioAgilytix and founder of the Legal Drugs podcast. She’s a podcaster, veteran business developer, social media strategist and consultant who kicked off her career in research who has held business development roles across pre-clinical research, bioanalysis and in basic research. They discuss how she fell in love with the service side of research and her advice for others interested the drug industry.

[EPISODE 6] Dr. Laura Sepp-Lorenzino Talks Gene Editing, Mentorships, and Making Big Moves!

Posted by BioAgilytix / /

In today’s episode, Chad sits down with guest scientist, Dr. Laura Sepp-Lorenzino the Chief Scientific Officer at Intellia Therapeutics. Laura is an innovative leader in drug discovery and the development of small molecules and nucleotide therapeutics. Pharma is in Laura’s blood as her mother, a pharmacist, encouraged her to pursue a career in the science. She shares how she went from studying biochemistry in Argentina and her pursuit of a Ph.D., then pivoting in a life-changing move to the United States. She also talks about the importance of paying it…

Taking Risks and Setting Precedent in Bioanalytical Assays for Cell & Gene Therapies

Posted by BioAgilytix / /

There are no bad ideas in developing bioanalytical testing, says Jim McNally, CSO of BioAgilytix. Not all ideas will work, of course. But he has found that it is the outside-the-box ideas that often turn out to be the solution in challenging assay work. Dr. McNally speaks with The Chain about his background in bioanalytical testing and supporting clinical trials, the exciting future of cell and gene therapies, and the importance of setting precedent in bioanalysis of these new, life-saving therapies. It is an exciting time for gene therapy especially,…